BioSpace News Archive

Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and twelve months ended December 31, 2019.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2019 after the close of the market on Monday, March 23, 2020.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today reported financial results for the three months and full year ended December 31, 2019.

Masimo (NASDAQ: MASI), a global leader in innovative noninvasive monitoring technologies, today announced it has entered into a definitive agreement to acquire TNI medical AG (“TNI”), an innovative ventilation company headquartered in Würzburg, Germany. In August 2019, Masimo disclosed an investment in TNI that included an exclusive option to acquire the company.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced its financial results for the year ended December 31, 2019 and provided a business update

Castle Connolly Private Health Partners, LLC (“CCPHP”), partnered with Infectious Disease expert Marisa Montecalvo, MD, to share important COVID-19 outbreak information through a “Be in the Know about COVID-19" Q&A webinar.

Amid the stringent travel bans the United States and European Union governments have enacted to slow the spread of COVID-19, there are some critical exceptions that need to be made, in order to save lives.

Sol-Gel Technologies, Ltd. announced the Company will report full year 2019 financial results and provide a corporate update on Tuesday, March 24th 2020, 4:05 PM ET.

Polarisqb has partnered with Fujitsu to create a ground-breaking drug discovery platform combining quantum-inspired technology, machine learning, hybrid quantum mechanics and molecular mechanics simulations.

Danaher Corporation announced that the U.S. Federal Trade Commission has accepted the proposed consent order in connection with Danaher’s definitive agreement with General Electric Company to acquire the Biopharma business of GE Life Sciences.